PROMACTA ¾àÁ¦ ÀλçÀÌÆ®¿Í ½ÃÀå ¿¹Ãø(2032³â)
PROMACTA Drug Insight and Market Forecast - 2032
»óǰÄÚµå : 1378360
¸®¼­Ä¡»ç : DelveInsight Business Research LLP
¹ßÇàÀÏ : 2023³â 11¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 30 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 2,750 £Ü 3,841,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 4,125 £Ü 5,762,000
PDF (2-3 User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 3¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 5,500 £Ü 7,682,000
PDF (Site License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,250 £Ü 11,524,000
PDF (Global License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¤± º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼Û±âÀÏÀº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

PROMACTA(¿¤Æ®·Òº¸ÆÄ±×) Á¤Á¦´Â °æ±¸¿ë ÀúºÐÀÚ Æ®·Òº¸Æ÷¿¡Æ¾(TPO) ¼ö¿ëü ÀÛ¿ëÁ¦ÀÎ ¿¤Æ®·Òº¸ÆÄ±× ¿Ã¶ó¹Î(Eltrombopag Olamine)À» ÇÔÀ¯Çϰí ÀÖ½À´Ï´Ù. ¹Ì±¹¿¡¼­´Â PROMACTA, ¹Ì±¹ ¿Ü ´ëºÎºÐÀÇ ±¹°¡¿¡¼­´Â Revolade¶ó´Â ºê·£µå¸íÀ¸·Î ÆÇ¸ÅµÇ°í ÀÖ½À´Ï´Ù. ÀÌ ¾àÀº ¸¸¼º ITP¶ó°í ºÒ¸®´Â ƯÁ¤ Ç÷¾× Áúȯ°ú ¸¸¼º CÇü °£¿° ȯÀÚÀÇ Ç÷¼ÒÆÇ ¼öÄ¡ ÀúÇϸ¦ Ä¡·áÇÏ´Â µ¥ »ç¿ëµË´Ï´Ù. Ç÷¼ÒÆÇÀº Ç÷ÀüÀ» Çü¼ºÇϰí ÃâÇ÷À» ¿¹¹æÇÏ´Â µ¥ ÇÊ¿äÇÑ Ç÷¾× ¼¼Æ÷ÀÇ ÀÏÁ¾ÀÔ´Ï´Ù. ¿¤Æ®·Òº¸ÆÐ±×´Â Ç÷¼ÒÆÇ ¼ö¸¦ Áõ°¡½ÃÄÑ ÃâÇ÷ À§ÇèÀ» °¨¼Ò½Ãŵ´Ï´Ù. ¿¤Æ®·Òº¸ÆÐ±×´Â ü³»¿¡¼­ Ç÷¼ÒÆÇÀ» »ý¼ºÇÏ´Â ÀÏÁ¾ÀÇ Ãµ¿¬ ¹°Áú(Æ®·Òº¸Æ÷¿¡Æ¾)ó·³ ÀÛ¿ëÇÕ´Ï´Ù.

6¼¼ ÀÌ»óÀÇ ´ëºÎºÐÀÇ ¼ºÀÎ ¹× ¼Ò¾Æ ȯÀÚ´Â ÇÁ·Î¸ÆÅ¸ 1ÀÏ 1ȸ 50mg, 1-5¼¼ ¼Ò¾Æ ȯÀÚ´Â 1ÀÏ 1ȸ 25mgÀ¸·Î ½ÃÀÛÇØ¾ß ÇÕ´Ï´Ù. °£¼Õ»ó ȯÀÚ ¹× ÀϺΠµ¿³²¾Æ½Ã¾Æ°è Ç÷ÅëÀÇ È¯ÀÚµéÀº ¿ë·® °¨¼Ò°¡ ÇÊ¿äÇÕ´Ï´Ù. Ç÷¼ÒÆÇ ¼ö¸¦ 50¡¿109/L ÀÌ»óÀ¸·Î À¯ÁöÇϵµ·Ï Á¶ÀýÇÕ´Ï´Ù. ¿¤Æ®·Òº¸ÆÐ±×´Â °æ±¸¿ë ÀúºÐÀÚ TPO ¼ö¿ëü ÀÛ¿ëÁ¦À̸ç, Àΰ£ TPO ¼ö¿ëüÀÇ ¸·Åõ°ú¼º µµ¸ÞÀΰú »óÈ£ ÀÛ¿ëÇÏ¿© °ñ¼ö Àü±¸¼¼Æ÷¿¡¼­ °ÅÇÙ¼¼Æ÷ÀÇ Áõ½Ä°ú ºÐÈ­¸¦ À¯µµÇÏ´Â ½ÅÈ£ Àü´Þ ij½ºÄÉÀ̵带 °³½ÃÇÕ´Ï´Ù.

ÁÖ¿ä 7°³±¹ÀÇ PROMACTA ½ÃÀå¿¡ ´ëÇØ Á¶»çÇßÀ¸¸ç, ½ÃÀåÀÇ °³¿ä¿Í 2023-2032³â ÆÇ¸Å ¿¹Ãø µ¥ÀÌÅÍ, °æÀï ±¸µµ ¹× ±¹°¡º° µ¿Çâ µîÀ» Á¦°øÇϰí ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¸®Æ÷Æ®ÀÇ ¼­·Ð

Á¦2Àå ¸é¿ª¼º Ç÷¼ÒÆÇ °¨¼ÒÁõ(ITP)¿¡ ´ëÇÑ PROMACTAÀÇ °³¿ä

Á¦3Àå °æÀï ±¸µµ(Ãâ½Ã Ä¡·á¹ý)

Á¦4Àå °æÀï ±¸µµ(ÈÄ±â ´Ü°è ½Å±Ô Ä¡·á¹ý)

Á¦5Àå PROMACTA ½ÃÀå Æò°¡

Á¦6Àå SWOT ºÐ¼®

Á¦7Àå ¾Ö³Î¸®½ºÆ®ÀÇ °ßÇØ

Á¦8Àå ºÎ·Ï

Á¦9Àå DelveInsightÀÇ ¼­ºñ½º ³»¿ë

Á¦10Àå ¸éÃ¥»çÇ×

Á¦11Àå DelveInsight ¼Ò°³

Á¦12Àå ¸®Æ÷Æ® ±¸ÀÔ ¿É¼Ç

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

“"PROMACTA Drug Insight and Market Forecast - 2032" ” report provides comprehensive insights about PROMACTA for immune thrombocytopenic purpura (ITP) in the seven major markets. A detailed picture of the PROMACTA for ITP in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the PROMACTA for ITP. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the PROMACTA market forecast analysis for ITP in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in ITP.

Drug Summary:

PROMACTA (eltrombopag) tablets contain eltrombopag olamine, small molecule thrombopoietin (TPO) receptor agonist for oral administration. This is marketed under the brand name PROMACTA in the US and Revolade in most countries outside the US. This medication is used to treat low platelet levels in people who have a certain blood disorder called chronic ITP or who have chronic hepatitis C. It may also treat people with a certain blood disorder (aplastic anemia). Platelets are a type of blood cell needed to form blood clots and prevent bleeding. Eltrombopag decreases your risk of bleeding by increasing the number of platelets. Eltrombopag acts like a certain natural substance (thrombopoietin) that causes the body to produce platelets.

Dosage

Persistent or chronic ITP: Initiate PROMACTA at 50 mg once daily for most adult and pediatric patients 6 years and older and at 25 mg once daily for pediatric patients aged 1-5 years. Dose reductions are needed for patients with hepatic impairment and some patients of East-/Southeast Asian ancestry. Adjust to maintain platelet count greater than or equal to 50 × 109/L. Do not exceed 75 mg per day.

Mechanism of action

Eltrombopag is an orally bioavailable, small-molecule TPO-receptor agonist that interacts with the transmembrane domain of the human TPO-receptor and initiates signaling cascades that induce proliferation and differentiation of megakaryocytes from bone marrow progenitor cell.

Scope of the Report:

The report provides insights into:

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

PROMACTA Analytical Perspective by DelveInsight

In-depth PROMACTA Market Assessment

This report provides a detailed market assessment of PROMACTA for immune thrombocytopenic purpura (ITP) in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2023 to 2032.

PROMACTA Clinical Assessment

The report provides the clinical trials information of PROMACTA for ITP covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

Key Questions:

Table of Contents

1. Report Introduction

2. PROMACTA Overview in ITP

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. PROMACTA Market Assessment

6. SWOT Analysis

7. Analysts' Views

8. Appendix

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â